53. Sjogren syndrome
234 clinical trials,   270 drugs   (DrugBank: 85 drugs),   49 drug target genes,   174 drug target pathways

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02334306
(ClinicalTrials.gov)
June 8, 201512/12/2014A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's SyndromeA Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's SyndromePrimary Sjögren's SyndromeBiological: AMG 557/MEDI5872;Other: PlaceboMedImmune LLCAmgenCompleted18 Years75 YearsAll32Phase 2United States;France;Sweden;United Kingdom
2EUCTR2014-003896-41-GB
(EUCTR)
27/03/201505/02/2015MedImmune Sjogren's Syndrome StudyA Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome Primary Sjogren’s Syndrome
MedDRA version: 18.1;Level: LLT;Classification code 10042846;Term: Syndrome Sjogren's;System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
MedImmune, LLCNULLNot Recruiting Female: yes
Male: yes
42Phase 2France;United States;United Kingdom;Sweden